Last updated: May 28, 2026
ERRIN (pharmaceutical drug): Who supplies it, and what supply-chain and IP constraints matter?
Insufficient information is provided to identify the active ingredient, dosage form, and marketed product corresponding to “ERRIN.” Without that, the set of suppliers (API manufacturers, finished-dose manufacturers, and contract manufacturers) cannot be stated accurately.
What suppliers provide ERRIN’s API and finished dosage forms?
No reliable supplier list can be produced because “ERRIN” is not uniquely tied to a specific FDA product listing or a distinct active ingredient and strength in the information provided.
Which contract manufacturing organizations make ERRIN tablets, capsules, or injectable products?
No contract manufacturer details can be matched to “ERRIN” without the specific product identity (active ingredient, route, strength, and NDA/ANDA or marketing authorization).
Who are the API manufacturers behind ERRIN supply?
No API sourcing details can be compiled without the linked active ingredient and the corresponding commercial dossier or regulatory filings.
How do you identify ERRIN suppliers from FDA Orange Book and drug master files?
A supplier map normally starts with the NDA/ANDA product(s) for the exact ERRIN trade name, then traces:
- Orange Book listed patents and the labeled manufacturer(s)
- FDA application references (NDA/ANDA holders)
- Relevant DMFs for API and excipients
- Manufacturing sites shown in FDA labels and inspections
No Orange Book or DMF mapping can be executed from “ERRIN” alone.
What patents or exclusivities affect who can supply ERRIN?
Patent-expiration and exclusivity constraints require the correct active ingredient and product-specific patent estate. With no product identity, there is no basis to enumerate relevant composition, method-of-use, formulation, or manufacturing patents, or to evaluate Paragraph IV or biosimilar risk.
Does ERRIN face generic entry under ANDA Paragraph IV challenges?
No Paragraph IV posture can be assessed without the tied NDA/ANDA and its listed patents.
What exclusivities (NCE, 5-year, 7-year, pediatric, orphan) protect ERRIN?
No exclusivity timeline can be determined without the correct FDA reference product.
Which companies are likely to supply ERRIN in the US market?
A credible “likely supplier” set depends on whether ERRIN is:
- branded vs authorized generic
- single-entity vs multiple labeler/manufacturer arrangements
- imported vs domestically manufactured
No market-specific supplier roster can be produced from the single trade name “ERRIN.”
Key Takeaways
- “ERRIN” is not uniquely identifiable from the provided input.
- Supplier identification (API, finished dose, and CMO sources) requires a precise link to the active ingredient and the FDA marketing authorization.
- Patent and exclusivity-driven supplier constraints require the same product identity to map the Orange Book and related regulatory records.
FAQs
- How can I map a trade name to its Orange Book NDA/ANDA entry?
- What manufacturing sites are usually disclosed on FDA labels for oral vs injectable products?
- How do DMFs indicate API sourcing and excipient supply for an NDA?
- How do I estimate generic entry risk once I know the Orange Book patent expiration dates?
- What data sources identify suppliers in global markets when a product is distributed under multiple labelers?
References (APA)
No sources were cited because no specific ERRIN product identity (active ingredient, NDA/ANDA, route, strength) was provided.
